|Articles|July 9, 2020

In Developing World, Pharmacies Can Play Important Role for HIV Patients

In developing countries with overcrowded hospitals, community pharmacies can relive burden, help HIV patients.

Adult patients living with HIV that were virologically suppressed remained virologically stable with optimal adherence and retention in care when willingly chose to refill prescriptions in Community Pharmacies (Co-Pharm) after transistioning away from hospital settings, according to a new study.

An overwhelming majority (98%) of the participants were retained in care, and 85% had optimal adherence.

“Patients remained virologically stable with optimal adherence and retention in care,” the investigators wrote.

These findings were presented at the International AIDS Society (IAS) AIDS 2020 Virtual Sessions.

In developing countries with overcrowded hospitals, community pharmacies can relive burden, help patients adhere to their regimen, thus offering a viable alternative to patients who need to maintain their medication and keep stable.

This study was done in Southern Nigeria from January 2017 to June 2019. The study included 2,938 patients who had a viral load of less than 20 copies/mL, and were recruited and enrolled in a community based program where patients refilled prescriptions in a registered Co-Pharm. Baseline log viral load(VL) was 3.7; no significant difference in median VL before and after participants devolved to the Co-Pharm. The before median VL = 2.9 log copies/mL versus after the median VL = 2.9 log copies/mL.

Twenty nine public hospitals and 64 registered community pharmacies were recruited. This was a non-randomized intervention study.

Sociodemographic and treatment data (medication regimen, prescription refill, retention in care and viral load) were collected. Baseline virologic suppression before patients devolved to the Co-Pharm was compared with the patients' virologic suppression data after 12 months of devolvement.

The World Health Organization has recommended using community-based models for scaling up HIV treatment.

“This [study] suggests that patients who are already virologically suppressed may remain stable even if they are devolved from the hospitals to the Co-Pharm,” the investigators concluded.


Related to this article

Ebola and the Ongoing Tale of US Failures
In mid-May, as the world was still grappling with an unexpected hantavirus outbreak aboard a tourism vessel, news broke of an Ebola outbreak in the Ituri Province of the Democratic Republic of the Congo spanning at least 3 health zones, including Bunia, Rwampara, and Mongbwalu.
This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Measles Update: September 18, 2026
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
CDC Responds to Surge in Rabies Exposures
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.